Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Saab AB (publ) (SAABY)

Other OTC - Other OTC Delayed Price. Currency in USD
25.980.00 (0.00%)
At close: 03:17PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close25.98
Open24.76
BidN/A x N/A
AskN/A x N/A
Day's Range25.98 - 25.98
52 Week Range15.05 - 31.71
Volume59
Avg. Volume451
Market Cap6.907B
Beta (5Y Monthly)0.68
PE Ratio (TTM)26.24
EPS (TTM)0.99
Earnings DateN/A
Forward Dividend & Yield0.26 (0.99%)
Ex-Dividend DateApr 10, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SAABY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SAAB AB UNSPN ADS EACH REP 0.5
    Analyst Report: Merck KGaAMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Reuters

    Saab eyes Colombia, Peru as potential Gripen clients amid Latam push

    Sweden's Saab AB is looking to boost sales of its Gripen fighter in Latin America, eyeing potential purchases by Colombia and Peru as it prepares to start producing the aircraft in Brazil in partnership with Embraer SA. Chief executive officer Micael Johansson told Reuters the company hopes the Colombian government will soon reopen procurement for fighter jets, while Peru is seen as a next potential market.

Advertisement
Advertisement